http://purl.org/np/RATgYbpNYn... RATgYbpNYn

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

https://dailymed.nlm.nih.gov/d...37-848b-45fd-9107-a6db5a675360 drugInfo.cfm?setid=5b8fb137-848b-45fd-9107-a6db5a675360

Leoni Bücken

2021-04-12T08:05:40.258Z

http://purl.org/np/RATgYbpNYn... RATgYbpNYn

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#value value

Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss

Leoni Bücken

2021-04-12T08:05:40.258Z

http://purl.org/np/RATgYbpNYn... RATgYbpNYn

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://purl.org/np/RATgYbpNYn...#medtherapy medtherapy

http://www.w3.org/ns/prov#wasDerivedFrom wasDerivedFrom

Leoni Bücken

2021-04-12T08:05:40.258Z